1. Home
  2. VTYX vs MDV Comparison

VTYX vs MDV Comparison

Compare VTYX & MDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • MDV
  • Stock Information
  • Founded
  • VTYX 2018
  • MDV 2015
  • Country
  • VTYX United States
  • MDV United States
  • Employees
  • VTYX N/A
  • MDV N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • MDV Transportation Services
  • Sector
  • VTYX Health Care
  • MDV Consumer Discretionary
  • Exchange
  • VTYX Nasdaq
  • MDV Nasdaq
  • Market Cap
  • VTYX 148.4M
  • MDV 156.7M
  • IPO Year
  • VTYX 2021
  • MDV 2022
  • Fundamental
  • Price
  • VTYX $1.73
  • MDV $16.13
  • Analyst Decision
  • VTYX Buy
  • MDV Strong Buy
  • Analyst Count
  • VTYX 5
  • MDV 1
  • Target Price
  • VTYX $8.40
  • MDV $18.00
  • AVG Volume (30 Days)
  • VTYX 1.1M
  • MDV 39.7K
  • Earning Date
  • VTYX 11-07-2024
  • MDV 11-06-2024
  • Dividend Yield
  • VTYX N/A
  • MDV 7.14%
  • EPS Growth
  • VTYX N/A
  • MDV N/A
  • EPS
  • VTYX N/A
  • MDV N/A
  • Revenue
  • VTYX N/A
  • MDV $47,416,592.00
  • Revenue This Year
  • VTYX N/A
  • MDV N/A
  • Revenue Next Year
  • VTYX N/A
  • MDV $1.91
  • P/E Ratio
  • VTYX N/A
  • MDV N/A
  • Revenue Growth
  • VTYX N/A
  • MDV N/A
  • 52 Week Low
  • VTYX $1.67
  • MDV $13.27
  • 52 Week High
  • VTYX $11.48
  • MDV $18.11
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 30.10
  • MDV 43.21
  • Support Level
  • VTYX $2.10
  • MDV $15.70
  • Resistance Level
  • VTYX $2.36
  • MDV $16.44
  • Average True Range (ATR)
  • VTYX 0.12
  • MDV 0.57
  • MACD
  • VTYX -0.05
  • MDV -0.07
  • Stochastic Oscillator
  • VTYX 8.76
  • MDV 21.39

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.

Share on Social Networks: